How is the CSL share price performing against its sector in 2022?

It has been a tough 2022 so far for CSL shareholders…

| More on:
A CSL scientist looking through a telescope in a lab

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • CSL shares edge 0.09% lower to $265.47 at Monday's closing bell
  • The company's shares have tracked relatively in line with the S&P/ASX 200 Health Care sector in 2022
  • However, CSL shares have fared slightly better when looking at a 12-month comparison

The CSL Limited (ASX: CSL) share price has wobbled since the beginning of the year.

This has been caused by a challenging environment brought about by the ongoing impacts of the global COVID pandemic.

At Monday's market close, the global biotech's shares finished 0.09% lower to $265.47.

Below, we take a look at the company's most recent performance, and comparison against its sector in 2022.

What's happened to CSL recently?

On February 16, CSL provided investors with its half-year results for the 2022 financial year. The CSL share price rose 8.5% on the back of the details.

The company noted that its immunoglobulin portfolio faced headwinds caused by industrywide constraints on collecting plasma in FY21. This was due to the global pandemic, with government-mandated restrictions causing foot traffic numbers to fall.

Under the CSL Behring banner, sales of its leading subcutaneous immunoglobulin product, Hizentra, fell 9%. Nonetheless, this contributed to overall revenue of US$4.4 billion for the CSL Behring portfolio, down 2% on H1 FY21.

Meanwhile, its Seqirus business experienced a strong surge in seasonal influenza vaccines, up 20%. A record volume of around 110 million doses was distributed around the world. As a whole, Seqirus revenue jumped to US$1.7 billion, up 17% from the prior corresponding period.

In addition, CSL responded by implementing multiple initiatives in its plasma collections network. Programs included using social media influencers, speeding up the donation sign-up and check-in process, and paying donors more for blood.

Investors were also updated on the company's plasma collection numbers, with volume up 18% over H1 FY21.

CSL opened 18 new facilities in the first half of FY22 to attract lapsed and new donors through its doors. For the remainder of the financial year, the company plans to open another 35 centres, expanding its presence, mostly across the United States.

Also in February, CSL announced the completion of a share purchase plan. The SPP – first announced in December – raised $750 million for CSL's acquisition of Vifor Pharma.

How does the CSL share price compare to the health sector?

Over the last 12 months, the CSL share price is more or less flat, but is down almost 8.7% this year to date. The company's shares hit a 52-week high of $319.78 in November 2021, before moving in circles.

In contrast, the S&P/ASX 200 Health Care Index (ASX: XHJ) has lost 2.6% from this time last year, and is down 11.3% in 2022. The sector also registered a record high of 48,213 points in late-August.

Both the CSL share price and broader health index are down around 3.5% over the past month.

As you can see, CSL shares are slightly tracking ahead of the Health Care Index. The latter has failed to take off this year amid the expected rise in interest rates which weakens investor sentiment.

Based on today's price, CSL commands a market capitalisation of roughly $127.88 billion, with approximately 481.71 million shares on issue.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

Guess which ASX 300 stock is crashing 55% today

What's going on with this stock? Let's see why investors are hitting the sell button.

Read more »

Woman serving customer in pharmacy.
Healthcare Shares

Up 132% in a year, are Sigma Healthcare shares still a good buy post the Chemist Warehouse merger?

After gaining 132% in 12 months, it too late to buy Sigma Healthcare shares today?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Share Market News

Is it too late to buy Pro Medicus shares?

Pro Medicus shares have risen 550% over 3 years. Have you missed the boat? Three experts weigh in.

Read more »

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

These 5 ASX 200 healthcare shares gained the most weight in FY25

These stocks were in great health last financial year.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Guess which ASX 300 healthcare stock is charging higher on product launch news

Investors have responded positively to this announcement.

Read more »

Three healthcare workers look and point at at medical image
Share Market News

Pro Medicus shares surge 10% to crack $300 as healthcare leads ASX 200 sectors

Pro Medicus shares just keep on going, rising 625% over the past three years.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Here are the latest growth forecasts for the CSL share price

Can this biotech giant deliver healthy returns?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Healthcare Shares

UP 127% in a year, why is the Pro Medicus share price rocketing higher again today?

ASX investors are sending Pro Medicus shares flying higher on Thursday. But why?

Read more »